Non-surgical periocular nodular-BCC treatments are successful
Imiquimod (IMQ) 5% cream and radiotherapy (RT) are both effective for treating periocular nodular-based cell carcinoma (BCC)
Imiquimod (IMQ) 5% cream and radiotherapy (RT) are both effective for treating periocular nodular-based cell carcinoma (BCC), according to a study published in the British Journal of Ophthalmology.
Dr Elena Garcia-Martin et al., Hospital Universitario Miguel Servet, Zaragoza, Spain, examined 27 patients with clinical and histopathological diagnosis of nodular BCC on the eyelid. IMQ 5% cream was administered in 15 patients once daily 5 days a week for 6 weeks. RT was performed in 12 patients.
Within 3 months of treatment all patients demonstrated histopathological remission. Sustained clinical remission was recorded in every patient after 24 months follow-up. Toleration of treatment for IMQ and RT was recorded as moderate and good, respectively.
The investigation concluded that the non-surgical methods of using IMQ and RT were successful in treating eyelid nodular BCCs. IMQ demonstrated better cosmesis and functional results, whereas RT demonstrated a better tolerability.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
